tbuckley/cabot-search huggingface dataset:
GM-0111, a modified glycosaminoglycan, to prevent radiation-induced mucositis.
Authors: Won Yong Lee, Justin R Savage, Kavita Gupta, Thomas P Kennedy, Glenn D Prestwich
Journal: Journal of Clinical Oncology (2015)

e20688 Background: Mucositis is an inflammatory disease that frequently develops during radiation and chemotherapy posing serious challenges to patients undergoing cancer treatments. Currently available treatments for mucositis largely rely on symptomatic relief. GM-0111 is a modified glycosaminoglycan that blocks various innate immune molecules such as TLRs and selectins. GM-0111 also broadly suppresses bacterial growth present in the oral cavity. We investigated whether these anti-inflammatory and anti-bacterial effects of GM-0111 could be exploited to prevent radiation-induced oral mucositis by testing in vitro and in vivo radiation-induced mucositis models. Methods: (1) In vitro studies: human oral epithelial cells (HOEPs) and mouse macrophage cells were treated with GM-0111 and irradiated with x-rays (10 Gy), and cell death was determined by flow cytometry assay using Annexin V/7-AAD binding to cells. (2) In vivo studies: BDF1 mice were subcutaneously treated with either saline or 30 mg/kg of GM-0111 once daily (Days -2 to 7). On Day 0, mice were irradiated with single dose X-rays at 20 Gy. On Day 8, we harvested tongue samples and determined the degree of inflammation by gross and histological examinations as well as detection of myeloperoxidase (MPO) in the tissues. Results: GM-0111 at 100 µg/mL significantly reduced x-ray-induced cell death in both HOEPs and macrophage cells. Mice treated with GM-0111 showed markedly reduced signs of inflammation in the tongue with decreased infiltration of polymorphonuclear leukocytes in the mucosa, thicker epithelial layer, and normal mucous glandular morphology than the saline treated group. MPO analysis confirmed our histological observations with significantly (p < 0.01) lower concentrations of MPO in GM-0111 treatment groups compared to vehicle treated groups (saline/20 Gy 206 ± 77 vs. GM-0111/20Gy 104 ± 27 mU/mg protein; normal 62 ± 23 mU/mg protein). Conclusions: GM-0111 reduces radiation-induced cell death and inflammation in the tongue and can potentially reduce clinical signs of oral mucositis that frequently occur during radiotherapy in cancer patients.
Colesevelam attenuates cholestatic liver and bile duct injury in Mdr2 -/- mice by modulating fecal bile acid composition and signaling
Authors: C.D. Fuchs, G. Paumgartner, E. Halilbasic, N. Leditznig, A. Wahlström, M. Stahlman, T. Stojakovic, H.-U. Marschall, M. Trauner
Journal: Journal of Hepatology (2017)
CRISPR/Cas9 Screens Reveal Epstein-Barr Virus-Transformed B Cell Host Dependency Factors
Authors: Yijie Ma, Michael J. Walsh, Katharina Bernhardt, Camille W. Ashbaugh, Stephen J. Trudeau, Isabelle Y. Ashbaugh, Sizun Jiang, Chang Jiang, Bo Zhao, David E. Root, John G. Doench, Benjamin E. Gewurz
Journal: Cell Host & Microbe (2017)
No evidence for higher risk of hepatocellular carcinoma occurrence or recurrence following direct-acting antiviral HCV therapy: a systematic review, meta-analyses, and meta-regression
Authors: R. Waziry, B. Hajarizadeh, J. Grebely, J. Amin, M. Law, M. Danta, J. George, G.J. Dore
Journal: Journal of Hepatology (2017)
Changing eating behavior by motivational and controlled program during 12 weeks reduce weight, cytokeratin 18 levels and steatosis in patient with NAFLD
Authors: N. Dynnyk, A. Svintsitsky, G. Solovyova, O. Baka, V. Chernyavskyi, I. Yarmenchuk, L. Hvozdetska
Journal: Journal of Hepatology (2017)
The Role of chemokine (C-C motif) ligand 2 and the diet influence in the energy metabolism
Authors: F. Luciano, N. Cabré, A. Hernandez-Aguilera, G. Baiges-Gaya, A. Garcia-Heredia, S. Fernández-Arroyo, J. Camps, J. Joven
Journal: Journal of Hepatology (2017)
A randomized, double-blind, placebo-controlled study to evaluate the efficacy of a multispecies probiotic mixture in obese non-alcoholic fatty liver disease
Authors: S.B. Ahn, D.W. Jun, W.K. Saeed, J.S. Lee, Y.J. Chae, H.W. Oh, J.Y. Jeong, H.T. Kang, E.C. Jang, B.-K. Kang
Journal: Journal of Hepatology (2017)
Dexamethasone, Rituximab and Cyclophosphamide (DRC) As Salvage Therapy for Waldenstrom Macroglobulinemia
Authors: Jonas Paludo, Jithma P Abeykoon, Amanda Shreders, Sikander Ailawadhi, Morie A. Gertz, Craig B. Reeder, Rebecca L King, Nelson Leung, Shaji Kumar, Robert A. Kyle, Francis K Buadi, Thomas M. Habermann, David Dingli, Thomas E. Witzig, Angela Dispenzieri, Martha Q. Lacy, Ronald S. Go, Wilson I Gonsalves, John A Lust, S. Vincent Rajkumar, Stephen Ansell, Prashant Kapoor
Journal: Blood (2016)
Geoepidemiology, clinical manifestations and outcome of a large cohort of primary biliary cholangitis patients in Greece
Authors: N.K. Gatselis, K. Zachou, V. Lygoura, K. Azariadis, P. Arvaniti, E. Spyrou, G. Papadamou, G.K. Koukoulis, G.N. Dalekos, E.I. Rigopoulou
Journal: Journal of Hepatology (2017)
The prognostic value of hepatic artery and portal vein involvement in patients with perihilar cholangiocarcinoma
Authors: M. Gaspersz, J. van Vugt, R. Coelen, J. Vugts, T. Labeur, J. de Jonge, W. Polak, J. IJzermans, C. Nio, T. van Gulik, F. Willemssen, B.G. Koerkamp
Journal: Journal of Hepatology (2017)
Abstract IA23: Enhancing anti-tumor immunity through selective inhibition of IDO1
Authors: Reid Huber
Journal: Clinical Cancer Research (2017)

Abstract Tryptophan catabolism serves as an important metabolic immunoregulatory checkpoint, functioning in anti-inflammatory, immunosuppressive and tolerance-inducing processes. Three distinct heme-containing enzymes—indoleamine 2,3-dioxygenase (IDO) 1, IDO2 and tryptophan 2,3-dioxygenase (TDO)—have the capacity to initiate the first and rate-limiting step in this metabolic process, catalyzing the conversion of tryptophan to kynurenine. A growing body of scientific evidence indicates that this pathway, and more specifically, the IDO1 enzyme, may be of fundamental importance to tumor immune evasion. Through the depletion of local tryptophan and the production of kynurenine and other downstream metabolites, IDO1 activity has been shown to have an anti-proliferative effect on T cells, to promote Treg differentiation and to bias dendritic cells and macrophages toward an immunosuppressive phenotype. Further, IDO1 expression is a negative prognostic factor across numerous cancer histologies. Therefore, the selective inhibition of IDO1 has emerged as an attractive therapeutic approach to enhance anti-tumor immunity. This presentation will review the immunologic basis for targeting tryptophan catabolism in cancer, describe the emerging preclinical and clinical data on epacadostat, a novel first-in-class selective IDO1 inhibitor, and discuss the therapeutic rationales for epacadostat-based combination immunotherapies. Citation Format: Reid Huber. Enhancing anti-tumor immunity through selective inhibition of IDO1. [abstract]. In: Proceedings of the AACR Precision Medicine Series: Targeting the Vulnerabilities of Cancer; May 16-19, 2016; Miami, FL. Philadelphia (PA): AACR; Clin Cancer Res 2017;23(1_Suppl):Abstract nr IA23.
The effect of sulindac, sulfide and sulfone on enzymes mediated by the aryl hydrocarbon receptor pathway in colon cells
Authors: Sara E. Bass, Henry P. Ciolino, Christopher J. MacDonald, Omar Memon, Grace W. Yeh
Journal: Cancer Research (2004)

1371   Sulindac, a non-steroidal anti-inflammatory drug, as well as its metabolites, sulfide and sulfone have demonstrated chemopreventive capabilities against several forms of cancer, most notably reducing the incidence and mortality of colorectal cancer. The mechanism underlying these effects remains unresolved; however, the metabolites appear to play important roles. In this study, a well-characterized human colorectal adenocarcinoma cell line, Caco-2, was used to investigate the effects of sulindac, sulfide and sulfone on the aryl hydrocarbon receptor (AhR) pathway and enzymes mediated by this pathway. EROD enzyme assays showed significant CYP1A1 activity in cells treated with sulfide (6-fold), and lesser activity in those treated with sulindac (2-fold) and sulfone (1.5- fold). To characterize steady state levels of mRNA, semi-quantitative PCR was conducted. Treatment of Caco-2 cells with 100 μM sulfide increased CYP1A1 mRNA levels by approximately 20-fold over controls, while 100 μM sulindac or sulfone treatment increased levels approximately 2-fold each. To determine whether the effect on steady state levels of CYP1A1 is being regulated through transcription via the AhR pathway, gene regulation experiments are being conducted. The presence of CYP1A1 hnRNA in Caco-2 cells treated with sulindac and sulfide has indicated a transcriptional mechanism for the change in steady state mRNA levels observed. The AhR pathway is the most well-accepted mechanism for CYP1A1 induction and thus its involvement is suggested by these results. As further evidence, luciferase reporter gene assays utilizing the XRE enhancer sequences are being conducted. In addition, electrophoretic mobility gel shift assays are being performed to look for evidence of an activated AhR in the nucleus. Initial results suggest that sulindac, mainly through its sulfide metabolite, interacts with the AhR pathway and induces CYP1A1 activity via XRE-driven transcription. Consequently, this effect may contribute to the protective effect of sulindac against colon cancer.
The emerging role of Enterococcus spp. and multidrug-resistant bacteria causing pyogenic liver abscesses
Authors: M.M. Mücke, J. Kessel, V.T. Mücke, K. Sosnowsky, M. Hogardt, C. Stephan, S. Zeuzem, V.A.J. Kempf, C.M. Lange
Journal: Journal of Hepatology (2017)
Should exercises be painful in the management of chronic musculoskeletal pain? A systematic review and meta-analysis
Authors: Benjamin E Smith, Paul Hendrick, Toby O Smith, Marcus Bateman, Fiona Moffatt, Michael S Rathleff, James Selfe, Pip Logan
Journal: British Journal of Sports Medicine (2017)

Background Chronic musculoskeletal disorders are a prevalent and costly global health issue. A new form of exercise therapy focused on loading and resistance programmes that temporarily aggravates a patient’s pain has been proposed. The object of this review was to compare the effect of exercises where pain is allowed/encouraged compared with non-painful exercises on pain, function or disability in patients with chronic musculoskeletal pain within randomised controlled trials. Methods Two authors independently selected studies and appraised risk of bias. Methodological quality was evaluated using the Cochrane risk of bias tool, and the Grading of Recommendations Assessment system was used to evaluate the quality of evidence. Results The literature search identified 9081 potentially eligible studies. Nine papers (from seven trials) with 385 participants met the inclusion criteria. There was short- term significant difference in pain, with moderate quality evidence for a small effect size of −0.27 (−0.54 to −0.05) in favour of painful exercises. For pain in the medium and long term, and function and disability in the short, medium and long term, there was no significant difference. Conclusion Protocols using painful exercises offer a small but significant benefit over pain-free exercises in the short term, with moderate quality of evidence. In the medium and long term there is no clear superiority of one treatment over another. Pain during therapeutic exercise for chronic musculoskeletal pain need not be a barrier to successful outcomes. Further research is warranted to fully evaluate the effectiveness of loading and resistance programmes into pain for chronic musculoskeletal disorders. PROSPERO registration CRD42016038882.
Treating the Symptom but Not the Underlying Disease in Infective Endocarditis
Authors: David P. Serota, Colleen S. Kraft, Melissa B. Weimer
Journal: JAMA Internal Medicine (2017)

This Teachable Moment shows that the current model of neglecting an underlying illness, in this case, opioid use disorder that led to an expensive and recurrent hospitalizations, should no longer be the standard of care.
Liver iron concentration in patients referred for hyperferritinemia: multicenter analysis of the different groups according to HFE mutations and transferrin saturation index, prediction of liver iron overload in Southern Europe
Authors: L. Zubiaurre, A. Castiella, E. Zapata, I. Urreta, P. Otazua, J.M. Alustiza, D. De Juan, E. Salvador, G. Letamendi, B. Arrizabalaga, A. Iribarren, J.I. Emparanza
Journal: Journal of Hepatology (2017)
Operational tolerance in allotransplantation by use of regulatory T cells with a MHC-specific chimeric antigen receptor
Authors: F. Noyan, K. Zimmermann, M. Hardtke-Wolenski, A. Knoefl, E. Schulde, R. Geffers, M. Hust, J. Huehn, M. Galla, M. Morgan, A. Jokuszies, M.P. Manns, E. Jaeckel
Journal: Journal of Hepatology (2017)
Increased prevalence of common NOD2 risk variants and bacterial infections in patients with liver cirrhosis of the INCA screening cohort
Authors: M.C. Reichert, M. Casper, E. Vandieken, C. Ripoll, A. Zipprich, A. Thiel, F. Grünhage, B. Appenrodt, F. Lammert
Journal: Journal of Hepatology (2017)
Faster Aspart Versus Insulin Aspart as Part of a Basal-Bolus Regimen in Inadequately Controlled Type 2 Diabetes: The onset 2 Trial
Authors: Keith Bowering, Christopher Case, John Harvey, Michael Reeves, Michael Sampson, Robert Strzinek, Ditte-Marie Bretler, Rikke Beck Bang, Bruce W. Bode
Journal: Diabetes Care (2017)

OBJECTIVE This multicenter, double-blind, treat-to-target, phase 3 trial evaluated the efficacy and safety of fast-acting insulin aspart (faster aspart) versus insulin aspart (IAsp) in adults with type 2 diabetes receiving basal insulin and oral antidiabetic agents. RESEARCH DESIGN AND METHODS The primary end point was HbA1c change from baseline after 26 weeks’ treatment. After an 8-week run-in to optimize basal insulin, subjects were randomized (1:1) to mealtime faster aspart (n = 345) or IAsp (n = 344), titrated using a simple daily patient-driven algorithm, plus insulin glargine U100 and metformin. RESULTS HbA1c change was –1.38% (faster aspart) and –1.36% (IAsp); mean HbA1c was 6.6% for both groups. Faster aspart demonstrated noninferiority versus IAsp in reducing HbA1c (estimated treatment difference [ETD] [95% CI] –0.02% [–0.15; 0.10]). Both treatments improved postprandial plasma glucose (PPG) control; the PPG increment (liquid meal test) was statistically significant in favor of faster aspart after 1 h (ETD [95% CI] −0.59 mmol/L [−1.09; −0.09]; −10.63 mg/dL [−19.56; −1.69]; P = 0.0198), but not after 2–4 h. Change from baseline in fasting plasma glucose, body weight, and overall severe/blood glucose–confirmed hypoglycemia rates (rate ratio [RR] [95% CI] 1.09 [0.88; 1.36]) were similar between treatments. Postmeal hypoglycemia (0−2 h) rates were 2.27 (faster aspart) and 1.49 (IAsp) per patient-year of exposure (RR [95% CI] 1.60 [1.13; 2.27]). CONCLUSIONS Faster aspart and IAsp were confirmed noninferior in a basal-bolus regimen regarding change from baseline in HbA1c. Faster aspart improved 1-h PPG with no differences in 2−4-h PPG versus IAsp. Overall hypoglycemia rates were similar except for an increase in 0−2-h postmeal hypoglycemia with faster aspart.
Characterization and evaluation of hepatic fibrosis degree in patients with chronic hepatitis B virus infection with normal transaminases
Authors: C.S. Juan, M. Casado, M. Gonzalez, S. Hallouch, E. Práxedes, A. Porcel, A. Gálvez, F. Anguita, J.L. Vega
Journal: Journal of Hepatology (2017)
Increased hepatitis B virus (HBV) specific IFN-γ and IL17A secretion by T cell subsets in HBV infected non transmitting mothers and their HBV negative new-borns: a Novel mechanism for prevention of HBV vertical transmission
Authors: A.K. Vyas, S. Patra, M. Islam, S.K. Sarin, N. Trehanpati
Journal: Journal of Hepatology (2017)
The Role of Vena Cava Filters for Injured Patients
Authors: Alistair J. Kent, Jonathan K. Aboagye, Elliott R. Haut
Journal: JAMA Surgery (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Surgery HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Surgery journal
Striving for Clarity About the Best Approach to Thyroid Cancer Screening and Treatment
Authors: Julie Ann Sosa, Quan-Yang Duh, Gerard Doherty
Journal: JAMA Surgery (2017)

Jennifer S. Lin, MD, MCR; Erin J. Aiello Bowles, MPH; Selvi B. Williams, MD, MPH; Caitlin C. Morrison, MPH
Long-term ovarian function in patients treated with CHOP or CHOP plus etoposide for aggressive lymphoma.
Authors: Julia Meissner, Diana Tichy, Sascha Dietrich, Thomas Schmitt, Marita Ziepert, Evelyn Kuhnt, Tanja Rixecker, Mathias Witzens-Harig, Michael Pfreundschuh, Anthony D. Ho
Journal: Journal of Clinical Oncology (2014)

e20584 Background: Premature ovarian failure despite transient recovery of cyclic ovarian function after chemotherapy has been reported after alkylating chemotherapy for breast cancer or Hodgkin’s lymphoma. In this study we assessed the long-term impact of CHOP-like regimens on ovarian function in patients (pts) with aggressive lymphoma. Methods: Long-term survivors after CHOP or CHOP plus etoposide treatment within the Mabthera International Trial or the NHL B1 trial of the German NHL Study Group were requested to respond to a questionnaire and to consent to blood sampling for hormone assessment. Results: A total of 46 of 81 contacted pts with a median age of 32.5 years (range 18-40) at time of chemotherapy responded to the questionnaire. The median follow-up after completion of treatment was 14 years (yrs). In 12 pts the menstrual status could not be assessed, mostly due to concurrent use of contraceptives. Among the remaining 34 pts, 16 pts reported regular menstrual bleeding (median age at time of data collection 41.5 yrs, range 34-49) and 18 pts had already experienced menopause (median age 51.5 yrs, range 38-56). In 8 of these 18 pts, amenorrhea had persisted after chemotherapy whereas in 10 pts menopause had occurred after transient regain of regular menstrual cycles (including 2 pts with child birth after treatment). The median age at last menstrual bleeding was 40 yrs (<40 in 6 pts, 40-44 in 7 pts, and 45-49 in 5 pts). Twenty two pts agreed to participate in laboratory analyses. Anti-Muller-hormone (AMH) as a marker of ovarian reserve was not detectable (<0.14 ng/ml) in pts with absent menstrual bleeding or in pts above age 41, while FSH levels were elevated in these patients. In younger (36-41 yrs), still menstruating pts, AMH levels (<0.14 ng/ml in 2 pts, 0.14-0.3 ng/ml in 3 pts, >0.3-1.4 ng/ml in 2 pts) were decreased when compared to age matched controls. Conclusions: Age at menopause was considerably lower in our post CHOP-like chemotherapy pt cohort compared to the general population in Western countries (51 yrs). In menstruating pts, AMH levels were low for age. We conclude that diminished ovarian reserve frequently occurs after treatment with CHOP-like regimens and thorough counseling of these patients is recommended.
In HBeAg-negative chronic HBV infection, HBsAg levels profoundly vary among different HBV-genotypes and can be influenced by the degree of HBsAg variability: can quantitative HBsAg truly reflect intra-hepatic HBV reservoir?
Authors: R. Salpini, A. Battisti, O. Anastasiou, U. Gill, L. Colagrossi, A. Bertoli, L. Fabeni, V. Fini, L. Piermatteo, A. Iuvara, V. Malagnino, C. Cerva, M. Lichtner, C. Mastroianni, G. De Sanctis, M. Paoloni, M. Marignani, C. Pasquazzi, N. Iapadre, T. Mari, G. Parruti, J. Vecchiet, L. Sarmati, M. Andreoni, M. Angelico, S. Grelli, P. Kennedy, J. Verheyen, C.F. Perno, V. Svicher
Journal: Journal of Hepatology (2017)
Use of ledipasvir/sofosbuvir in patients with advanced chronic kidney disease (eGFR ≤ 30 mL/min): a case series
Authors: M.E. Sise, N. Alkhouri, B. Borg, T. McQuaid, J. Llewellyn, M. Natha, S. De-Oertel, D.M. Brainard, M. Carp, M. Fuchs, H. Gilles, S. Satapathy, D. Hazar, S. Nair, N. Reau
Journal: Journal of Hepatology (2017)
Abstract IA18: The post-transcriptional response to bulky-adduct DNA damage
Authors: Anne E. Willis
Journal: Cancer Research (2017)

Abstract Under conditions of physiological cell stress, including those that are found within a tumor cell and following treatment with chemotoxic drugs that cause DNA damage, post-transcriptional control pathways are initiated to aid cell survival. Global rates of protein synthesis are reduced by altering the phosphorylation status of eukaryotic initiation factors (eIFs), leading to decreases in the levels of ternary complex (required to bring the initiator Met-tRNAi to the 40S ribosomal subunit) and eIF4F complex (which binds to the 7methyl G cap). In parallel with protein synthesis shut down there is reprogramming of the translatome to allow the translation of “survival” mRNAs, which is mediated by RNA motifs within their 5' and 3' untranslated regions (UTRs) and their interaction with RNA binding proteins. Interestingly, the data show that this re-programming of the translatome is dependent upon the type of DNA damage initiated. For example, we have shown that following treatment with agents that cause bulky-adduct DNA damage, such a platinum-based compounds (cisplatin, oxaliplatin) or mitomycin C, the polysomes are enriched with mRNAs that encode enzymes that function in nucleotide excision repair. We have shown that these mRNAs contain regulatory upstream open reading frames (uORFs). Importantly, we have identified a common polymorphism in an uORF in the 5' UTR of the critical DNA repair enzyme ERCC5 and show that this determines sensitivity to platinum-based chemotherapy by controlling ERCC5 translation. Signaling from DNA-PKcs to eIF2 is required as part of this response, and modulation of this pathway alters the synthesis of critical repair enzymes and can chemosensitize cells to treatment with platinum-based compounds. We have used RNA-interactome capture to examine changes in the interactions of RNA binding proteins with their target mRNAs following bulky adduct-DNA damage and have identified a cytoplasmic RNA-BP complex that responds specifically to this type of DNA damage. Citation Format: Anne E. Willis. The post-transcriptional response to bulky-adduct DNA damage. [abstract]. In: Proceedings of the AACR Special Conference on Translational Control of Cancer: A New Frontier in Cancer Biology and Therapy; 2016 Oct 27-30; San Francisco, CA. Philadelphia (PA): AACR; Cancer Res 2017;77(6 Suppl):Abstract nr IA18.
Low hepatitis C virus prevalence among human immunodeficiency virus+ individuals in Sub-Saharan Africa
Authors: A. Loarec, L. Molfino, K. Walter, W. Muyindike, V. Carnimeo, I. Andrieux-Meyer, S. Balkan, Y. Nzomukunda, D. Maman, J. Mwanga-Amumpaire, H. Bygrave
Journal: Journal of Hepatology (2017)
Polatuzumab Vedotin Combined with Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) for Patients with Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL): Updated Results of a Phase Ib/II Study
Authors: Hervé Tilly, Franck Morschhauser, Nancy L Bartlett, Jeff Sharman, Corinne Haioun, Kathryn S. Kolibaba, Andy Chen, Thierry Lamy, Surai Jones, Elicia Penuel, Calvin Lee, Gilles A. Salles
Journal: Blood (2016)